Ph 2 / 3 Study in Subjects With MPM w / Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Status: Active


This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma with low argininosuccinate synthetase 1 expression. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.

Eligibility Criteria

Inclusion Criteria

  • Histologically proven advanced MPM of biphasic or sarcomatoid histology. Biphasic MPM is defined using the World Health Organization's international histological classification of tumors as containing an epithelial and a sarcomatoid component with each component comprising at least 10% of the tumor
  • Naïve to prior chemotherapy or immunotherapy (i.e., this is a first-line systemic therapy study).
  • MPM tumor sample for determination of ASS1 status. ASS1-deficiency is not required for study entry at study start, but tumor sample for ASS1 status is required. This study will employ an adaptive biomarker-driven design with an interim analysis to be conducted at the end of the phase 2 portion. The interim analysis will evaluate the treatment effect of ADI PEG 20 in combination with pemetrexed and cisplatin on overall survival (OS) in the overall population (biphasic and sarcomatoid histology patients) and pre-defined subpopulation of biomarker-positive patients (ASS1-deficient subpopulation). Thus ASS1 deficiency may be required for the phase 3 portion of the study, pending the interim analysis. ASS1-deficiency, demonstrated on tissue specimen (cytospin samples are not acceptable), will be defined in the laboratory manual. If archived tissue is not sufficient or not available, then tissue must be obtained by biopsy.
  • Measurable disease as assessed by modified RECIST for MPM for thoracic disease (Appendix A) and RECIST 1.1 for extra-thoracic disease (Appendix B).
  • ECOG performance status of 0 - 1 (Appendix C).
  • Predicted life expectancy of at least 12 weeks.

Exclusion Criteria

  • Radiotherapy (except for palliative reasons) the previous two weeks before.
  • Ongoing toxic manifestations of previous treatments.
  • Symptomatic brain or spinal cord metastases (patients must be stable for > 1 month post radiotherapy or surgery).
  • Major thoracic or abdominal surgery from which the patient has not yet recovered.
  • Serious infection requiring treatment with intravenous antibiotics at the time of study entrance, or an infection requiring intravenous therapy within 7 days prior.
  • Known to be serologically positive for human immunodeficiency virus (HIV). Testing to determine possible infection status is not required.

Locations & Contacts


Mayo Clinic in Arizona
Status: Active
Name Not Available


Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: Active
Contact: Kim Kelly
Phone: 310-206-8309
San Francisco
UCSF Medical Center-Mount Zion
Status: Active
Name Not Available


Moffitt Cancer Center
Status: Active
Name Not Available


University of Chicago Comprehensive Cancer Center
Status: Active
Name Not Available


University of Maryland / Greenebaum Cancer Center
Status: Active
Contact: Brett Goldberger
Phone: 410-328-1160


Mayo Clinic
Status: Active
Name Not Available

New York

New York
Memorial Sloan Kettering Cancer Center
Status: Active
Name Not Available


M D Anderson Cancer Center
Status: Active
Name Not Available

Trial Phase & Type

Trial Phase

Phase II/III

Trial Type


Lead Organization

Lead Organization
Polaris Group

Trial IDs

Primary ID POLARIS2015-003
Secondary IDs NCI-2017-00005 ID NCT02709512